CytoSorbents Corporation announced at the 2026 Life Sciences Forum that it has scheduled two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs. CytoSorbents Corporation is a life sciences company that develops and commercializes medical devices and pharmaceutical-based products for the treatment of extracorporeal blood purification. extracorporeal blood purification industry.
